ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
6,044.80
-0.04%
US Tech 100
20,626.40
0.07%
Dow Jones
44,699.35
-0.18%
Brent Oil
73.795
2.65%
Bitcoin
95,429.28
-0.45%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Marker Therapeutics Inc (MRKR) Quote

Marker Therapeutics Inc

Marker Therapeutics Inc (MRKR)

NASDAQ
3.42
-0.22
( -6.04% )
Updated: 13:38:42
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
3.42
Bid
3.40
Ask
3.70
Volume
8,540
3.3798 Day's Range 3.65
2.4377 52 Week Range 6.1568
Market Cap
30.516M
Previous Close
3.64
Open
3.64
Last Trade
181
@
3.42
Last Trade Time
13:38:42
Financial Volume
$ 30,153
VWAP
3.5308
Average Volume (3m)
36,291
Shares Outstanding
8,922,695
Dividend Yield
-
PE Ratio
-3.66
Earnings Per Share (EPS)
-0.92
Revenue
3.31M
Net Profit
-8.24M

About Marker Therapeutics Inc

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops prod... Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart. Show more

Sector
Pharmaceutical Preparations
Industry
Business Services, Nec
Website
www.markertherapeutics.com
Headquarters
Wilmington, Delaware, USA
Founded
2006
Marker Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker MRKR. The last closing price for Marker Therapeutics was $3.64. Over the last year, Marker Therapeutics shares have traded in a share price range of $ 2.4377 to $ 6.1568.

Marker Therapeutics currently has 8,922,695 shares outstanding. The market capitalization of Marker Therapeutics is $32.48 million. Marker Therapeutics has a price to earnings ratio (PE ratio) of -3.66.

Ask ADVFN Intelligence (AI)

MRKR Latest News

More News

Form S-3 - Registration statement under Securities Act of 1933

November 27 2024
Edgar (US Regulatory)

Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit

HOUSTON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies...

November 26 2024
GlobeNewswire Inc.

Form 8-K - Current report

November 14 2024
Edgar (US Regulatory)

Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

HOUSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies...

November 14 2024
GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

November 14 2024
Edgar (US Regulatory)

Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors

CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing...

August 28 2024
GlobeNewswire Inc.

Form 8-K - Current report

August 14 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

August 14 2024
Edgar (US Regulatory)

Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates

Preliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in Phase 1 APOLLO study MT-601 was well tolerated with no observation of...

August 14 2024
GlobeNewswire Inc.

Form 8-K - Current report

August 12 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.123.636363636363.33.653.04219133.37081674CS
4-0.19-5.263157894743.614.42.8205297733.47123882CS
120.23317.314317989273.18695.022.4377362913.4002034CS
26-0.44-11.39896373063.865.992.4377318433.82828262CS
520.7528.08988764042.676.15682.4377404424.27936747CS
156-7.88-69.734513274311.312.60.67064001144.52553673CS
260-27.78-89.038461538531.237.70.670659722015.94111168CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CTNTCheetah Net Supply Chain Service Inc
$ 5.24
(180.21%)
107.44M
ZJKZJK Industrial Company Ltd
$ 14.68
(131.55%)
20.43M
GWAVGreenwave Technology Solutions Inc
$ 0.6048
(65.70%)
399.39M
JYDJayud Global Logistics Ltd
$ 1.0792
(61.05%)
9.35M
JANXJanux Therapeutics Inc
$ 62.185
(54.77%)
5.28M
REVBRevelation Biosciences Inc
$ 0.5532
(-41.76%)
3.83M
OMEXOdyssey Marine Exploration Inc
$ 0.4752
(-36.23%)
3.53M
STSSSharps Technology Inc
$ 2.235
(-33.36%)
377.67k
CYCNCyclerion Therapeutics Inc
$ 1.61
(-31.20%)
266.25k
GELSGelteq Ltd
$ 2.703
(-29.25%)
224.97k
GWAVGreenwave Technology Solutions Inc
$ 0.6048
(65.70%)
399.45M
SMCISuper Micro Computer Inc
$ 40.86
(-2.71%)
169.47M
CTNTCheetah Net Supply Chain Service Inc
$ 5.24
(180.21%)
108.99M
CHRSCoherus BioSciences Inc
$ 1.88
(37.23%)
102.71M
NVDANVIDIA Corporation
$ 138.9509
(0.23%)
101.13M

MRKR Discussion

View Posts
Flyingj Flyingj 2 hours ago
Just curious. If mrkr is successful advancing there therapy, what will it take for patients to bypass car-t all together and go straight to markers therapy?
👍️ 1
GoIrish1776 GoIrish1776 2 hours ago
They did add a sixth antigen for this trial. They thought that would have greater efficacy. That's not wrong. In the context of six, however, I think Vera believes (hopes) that dose is what matters. There are a lot of confounding factors. It's a bit of a Rubik's cube.

I'm glad they are being disciplined about releasing data. A huge part of their problem has been dribs and drabs of data that is interesting but not overwhelming. We shall see where we stand within a month.
👍️0
CorsairNavigator20 CorsairNavigator20 3 hours ago
Thanks you were paying more attention to the discussion than I was. I thought their original reason to increase markers was to increase capture of more cancer cells which went with the idea that does was not the main issue.
👍️0
GoIrish1776 GoIrish1776 4 hours ago
He said, if memory serves, if he were being optimistic, efficacy depends on the dose level. However, he mentions that many factors could influence efficacy, including disease "load," expression of antigens, strength of the individual's immune system, etc. Also, the dose-response argument conflicts with what was published in the Baylor trial, where epitope spread correlates with stable disease, and they explicitly say there doesn't seem to be a correlation between dose and efficacy.

https://markertherapeutics.com/wp-content/uploads/VasileioouS21.MultiTAA.lymphoma.pdf
👍️ 1
CorsairNavigator20 CorsairNavigator20 5 hours ago
I think he said the number of markers on a cancer cell will determine the success rate. If that's the key, he needs to know that for an FDA discussion on phase 2. If they can create a test prior to treatment, it would be a huge step forward for some but not all relapsed patients. I'm waiting for the data and discussion.
👍️0
Flyingj Flyingj 14 hours ago
I couldn't tell from watching Vera if marker has a therapy that will make it to phase two or not. I guess will have to wait a little longer.
👍️0
GoIrish1776 GoIrish1776 16 hours ago
https://wsw.com/webcast/jmp66/mrkr/1699092

Everyone should watch for themselves.
👍️ 1
learningcurve2020 learningcurve2020 21 hours ago
Based on Vera's comments you have to wonder how analyst Hisaynov came up with his valuation? 
❌️ 1
Flyingj Flyingj 23 hours ago
Thanks
👍️0
CorsairNavigator20 CorsairNavigator20 1 day ago
I believe he said one still has had a CR for 9 months and one he seemed to give a fuzzy answer as to that persons status. He did note results are variable and one issue is the amount of flags on the cancer cells. The implication was the more markers the higher chance of success. They are investigating but said nothing concrete about the actual reason(s). I'm waiting for year end to see the data. Moderator did push for answers.
👍️ 1
Flyingj Flyingj 1 day ago
Did he say anything new about the 3 patients? Are they still doing well
👍️0
learningcurve2020 learningcurve2020 1 day ago
The usual biotech dangling a carrot routine.  Update on trial coming very soon (2024) he says but only commits to the three patients already public.  I don't like any of it but will wait to see.  Seems like a one man show.  Speaks of need for another trial. It's like a brand new company starting from scratch.  Market cap already reflects that so hopefully maintains current share price. Truly good news and buyout hopefully. 
👍️ 1 🚫 1 ❌️ 1
ShadowHaven59 ShadowHaven59 1 day ago
Thank you, did it help with your confidence in the company? Anything about the future of the company? Any plans?
👍️0
CorsairNavigator20 CorsairNavigator20 1 day ago
Just got off the jmp call, Vera says he will release the entire data set by the end of the year. He feels good about the data. Otherwise he still talks about the three patients.
👍️ 1
CorsairNavigator20 CorsairNavigator20 1 day ago
It was sold to Wilson Wolfe when they needed money. Back then, they were going to be all things all at once. I am sad they did it since it is like a dilution. That manufacturing process was their prized possession. I think it really motivates him to succeed.
Somebody has to lead even if he's in the backroom
👍️ 1
learningcurve2020 learningcurve2020 1 day ago
They sold it to a board member who now becomes a contractor so not ideal with silent management, IMO. 

* MARKER THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $300 MILLION – SEC FILING* MARKER THERAPEUTICS : SALES AGREEMENT PROSPECTUS COVERS OFFERING OF UP TO $11.4 MILLION OF COMMON STOCK THAT MAY BE ISSUED FROM TIME TO TIME 
👍️ 1
ShadowHaven59 ShadowHaven59 2 days ago
Does it help or hurt,the company sold their contract development and manufacturing to cell ready in partnership or buyout?
👍️0
CorsairNavigator20 CorsairNavigator20 3 days ago
Just my thoughts are the phase 1 data could drive us to $250M. Phase2 would not be completed in 2025 and I would be hoping 500-750M. The real driver would be the pancreatic cancer study next year. That phase 1 data could drive it since the study group could have 3-6 months to end of life. I look to the company value rather than stock price. They released notice for a secondary that will dilute us by 30%. Honestly not planning on buying more but looking to rent a house on the beach in Hawaii
👍️ 1
ShadowHaven59 ShadowHaven59 4 days ago
Unfortunately, my average is $18.24, I also have had the stock for a long time and would love $75 to get a nice profit. Lol people can dream lol
👍️ 1
microcapbiotech microcapbiotech 4 days ago
Well, being that I got enough for a new Ferrari into this over the last 25 years, and haven't sold yet, I'm holding as I am still WAY DOWN.
If it gets to $20 (from here without any splits), I'll be well into profit land. Getting bought out at $40 would be just fine with me, but your $75 sounds even better.
👍️ 1
ShadowHaven59 ShadowHaven59 4 days ago
Can I ask a question to you guys or ladies? If the company announces Good results and shares good news about the enrollment of patients and also the future of the company. Will you guys sell or hold? My next question would be, what price would you then give the company?? I’m hoping for a buyout next year of $75, not sure if that’s too high or if I’m asking for too much. Thank you.
👍️0
microcapbiotech microcapbiotech 4 days ago
"Originally the trial was supposed to enroll 37 patients. No reason it should not be fully enrolled by now at 37 patients. The next data release better be at least 30 patients. There is no excuse for anything less than that."
I HOPE THAT YOU ARE CORRECT. Any excuse after this much time to enroll will just be BS.
👍️ 1
ShadowHaven59 ShadowHaven59 5 days ago
Happy Thanksgiving to all! Thank you for all the valuable information. You guys post. Hopefully Monday there will be some good news.
👍️0
Phantom Lord Phantom Lord 6 days ago
They aren't meeting with retail investors. They are looking to meet with investment firms for a future capital raise.
👍️0
CorsairNavigator20 CorsairNavigator20 6 days ago
According to the jmp conference Dr Vera is going to be talking to registered investors. Anybody on this site going to have a chat with him
👍️0
learningcurve2020 learningcurve2020 6 days ago
Never be embarrased for biotech management because they always seem to do just fine for themselves.  It's the silent shareholders who deserve to be embarrassed.  
👍 1
Buckboard Buckboard 7 days ago
Thanks
👍️0
CorsairNavigator20 CorsairNavigator20 7 days ago
One would hope not. I could feel embarrassed for him if that is the case. Waiting to see if he will talk about trends in the data.
👍️ 2
learningcurve2020 learningcurve2020 7 days ago
Hallelujah!  Better not be just three trial patients.  
👍️0
jobynimble jobynimble 7 days ago
https://www.globenewswire.com/news-release/2024/11/26/2987657/0/en/Marker-Therapeutics-to-Present-at-the-Citizens-JMP-Hematology-and-Oncology-Summit.html

Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit
November 26, 2024 11:00 ET
| Source: Marker Therapeutics

HOUSTON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that Juan Vera, M.D., President and Chief Executive Officer of Marker Therapeutics, will present at the Citizens JMP Hematology and Oncology Summit. This investor event will be held virtually on December 2, 2024.

Dr. Vera will present an overview of Marker’s technology and clinical developments on Monday, December 2, 2024, at 11 AM EST.

Click above link for full release…
👍️ 1
ShadowHaven59 ShadowHaven59 1 week ago
Could it be the conference on Monday, why they were taking extra time to prepare the final data? Hopefully they release news on Monday. let’s see a run up on the stock price before the conference.
👍️ 2
learningcurve2020 learningcurve2020 1 week ago
Yup, Vera is still on their board.  Guess he couldn't sell a Marker takeover.  Anyone here ever ask him about it? 

https://www.allovir.com/our-people/juan-f-vera-md
👍️0
ShadowHaven59 ShadowHaven59 1 week ago
The company responded to me on 11/12 and 11/15 hopefully they’re trying to get better. I just like that the same information the analyst received, so did I.
👍️0
learningcurve2020 learningcurve2020 1 week ago
There's that "Runway" language again. AlloVir cut their staff and are using their remaining $100M for a new drug in a new indication instead of simply taking over Marker where they could've put their off the shelf T-cell knowledge to good use.  

>>The merged company is expected to have $100 million in the bank, which is set to pave a cash runway into the final months of 2026. AlloVir’s stockholders will own 25.05% of the resulting entity, with Kalaris’ stockholders owning the other 74.95%.



https://www.fiercebiotech.com/biotech/struggling-allovir-finds-new-identity-merging-eye-disease-biotech
👍️0
learningcurve2020 learningcurve2020 1 week ago
Thanks. What were the dates on those emails?...How much time has gone by?
👍️0
learningcurve2020 learningcurve2020 1 week ago
Not important, I guess.  LOL
👍️0
ShadowHaven59 ShadowHaven59 1 week ago
Yes, no problem, the first email I previously spoke about was the lack of transparency from the company and keeping the shareholders in the dark about the data from all the trials. The company responded agreeing with me and said they will work on trying to be more transparent and also keeping the shareholders more up-to-date. the company said they are currently working a comprehensive data update and are looking forward to sharing this information with our investors after completion of some remaining details. we appreciate your patience. this was the same information that the company told the analyst. The second email was just basically asking the CEO and upper management to buy shares in the open market if they believe in the company and the platform. Maria responded by thanking me and she said that she will forward the message to upper management.
👍️0
CorsairNavigator20 CorsairNavigator20 1 week ago
Do you care to share your discussions with them
👍️ 1
ShadowHaven59 ShadowHaven59 1 week ago
I’ve noticed a change in the frequency of responses from the company lately. in the last two years, I have never received a response, but in the last two months, I have received a response from my last two emails to the company, not sure it means anything, but I thought I would just post it in the chat room anyway. thank you everyone for your valuable information.
👍️0
learningcurve2020 learningcurve2020 1 week ago
Have you ever asked them why they don't address their shareholders on quarterly calls /Q&A but instead seem to rely on you to communicate? 
👍️0
Phantom Lord Phantom Lord 2 weeks ago
It's grant money.
👍️0
microcapbiotech microcapbiotech 2 weeks ago
Interesting cancer article. "Groundbreaking clinical trial cures cancer in 100% of patients."
https://www.msn.com/en-us/health/other/groundbreaking-clinical-trial-cures-cancer-in-100-of-patients/ar-AA1uqFJg?ocid=msedgdhp&pc=U531&cvid=be9d60cda7174620ee78a7879d0f9022&ei=45
Which brings up a question that I asked about 2 years ago, WHY doesn't MRKR use their Multi TAA, (now called MAR) ALONG WITH a checkpoint inhibitor that blocks the PD-1 protein on T-cells? Never got an answer to that.
👍️ 1
Flyingj Flyingj 2 weeks ago
Anybody know where the 1.92 million in sales came from this quarter? Is part of it right to try patients
👍️0
Phantom Lord Phantom Lord 2 weeks ago
Very tight lipped on the data. Just that they are encouraged by what they are seeing but I would expect them to say that regardless of what is happening with the trial.
👍️ 1
ShadowHaven59 ShadowHaven59 2 weeks ago
Thank you
👍️0
learningcurve2020 learningcurve2020 2 weeks ago
I never imagined a one trick pony biotech could put out a fresh 10q and forget to update their shareholders on the trial.  Seems impossible.  
👍️0
CorsairNavigator20 CorsairNavigator20 2 weeks ago
Were you able to ask about data subsets. My line of conjecture would be they saw a commonality in patients with good outcomes, approached the FDA to narrow the indication and had to increase sample size. Only positive reason why it's taking forever. Yes that will really change the future of this company. Just trying to keep a positive spin. Were you able to get them to talk data at all or tell you it is going to be the greatest thing since sliced bread.
👍️0
learningcurve2020 learningcurve2020 2 weeks ago
If the treatment is showing good efficacy it should be a cinch to enroll such small numbers.  So it begs the question, why would they sabotage their own company? 
👍️0
learningcurve2020 learningcurve2020 2 weeks ago
Not a good sign for Marker, IMO.  Should've been Marker not Kalaris.  Nobody wants to talk about here, of course. 

https://www.biopharmadive.com/news/allovir-kalaris-reverse-merger-retina-diseases/732385/
👍 1
Phantom Lord Phantom Lord 2 weeks ago
This is only partly true. They stopped the MT401 AML PII trial to refocus their efforts in AML on the OTS version of MT401. That trial was supposed to start by the end of this year but true to form the company blew right by their own timeframe. It's supposed to start first half of next year now, IIRC. Who really knows if this will end up being the right decision or not.
👍️ 2

Your Recent History

NASDAQ
MRKR
Marker Therapeutics
USOTC
KWBRY
Kepler Weber (PK)
BIT
EGLA
Euro Group Laminations
LSE
BUT
Brunner Investment
LSE
0E6R
St Dupont
DOWI
DJTSSS
DJ US Thematic Short Size
LSE
ADA
Adams
BIT
1A
Agilent Technologies
USOTC
MGON
Megola (PK)
LSE
0GUX
Skandinaviska Enskilda B...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved